Related Experiment Video
Updated: Jan 15, 2026

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test
Published on: April 9, 2012
Children, caregivers and health workers' perceptions and experiences of the XTEMP-R tool to improve tuberculosis
Dillon T Wademan1, Willdon J Filander1, Mfundo Mlomzale1
1Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Insights
The XTEMP-R tool simplifies preparing pediatric drug-resistant tuberculosis (DR-TB) medications at home, easing caregiver burden. However, taste and side effects remain challenges for children undergoing DR-TB treatment.
Area of Science:
- Pediatric infectious diseases
- Pharmaceutical technology
- Global health
Background:
- Treating pediatric drug-resistant tuberculosis (DR-TB) is challenging due to limited child-friendly formulations and poor palatability.
- Extemporaneous preparation of TB medications is a strategy to improve administration but often requires unavailable pharmaceutical services in high-burden settings.
Purpose of the Study:
- To explore the experiences and perceptions of children, caregivers, and health workers with the XTEMP-R tool for preparing pediatric DR-TB medication suspensions.
- To assess the usability and impact of the XTEMP-R tool on home-based treatment preparation and administration.
Main Methods:
- Qualitative study conducted in South Africa involving interviews and focus group discussions with caregivers and health workers.
- Interviews with caregivers of children who used the XTEMP-R tool for home administration of DR-TB treatment.
- Deductive thematic analysis of collected qualitative data.
Main Results:
- Participants found the XTEMP-R tool easy to use, clean, and store, with appealing design features.
- The tool simplified treatment preparation and administration, reducing burdens for home users.
- While usability was improved, challenges with medication palatability, nausea, and side effects persisted.
Conclusions:
- The XTEMP-R tool shows potential for easing pediatric DR-TB treatment preparation and administration.
- Further design refinement is needed to address medication palatability and side effects.
- The tool may foster increased treatment responsibility and agency in children, potentially improving adherence.
Abstract:
Treating drug-resistant tuberculosis (DR-TB) in children remains a significant challenge for patients, caregivers, and health systems, despite advances in child-friendly drug formulations. While new formulations offer benefits, their widespread availability is limited, and many exhibit poor palatability. A key strategy to improve administration and mask the taste of paediatric TB medications involves creating extemporaneous suspensions. However, this often requires pharmaceutical services not readily available in high-burden settings. To address this, the Global Alliance for TB Drug Development (TB Alliance) developed XTEMP-R, an inexpensive prototype tool designed to facilitate home-based preparation of liquid TB medication suspensions. This study explored the experiences and perceptions of children, their caregivers, and health workers regarding the XTEMP-R tool for preparing extemporaneous DR-TB treatment suspensions. We collected qualitative data from two sites in South Africa. The first component involved interviews with 17 caregivers and 12 health workers, followed by focus group discussions, with participants directly interacting with the XTEMP-R tool. The second component comprised 31 interviews with 11 caregivers of 13 children who used the XTEMP-R tool for home administration. Case descriptions were iteratively refined and analyzed using deductive thematic analysis. Findings indicate that children, caregivers, and health workers found the XTEMP-R tool easy to use, clean, and store, appreciating its appealing color and durability. Home users reported that the tool simplified treatment preparation and administration, reducing time and relational burdens associated with DR-TB treatment. While XTEMP-R effectively addressed usability challenges related to drug preparation, fundamental obstacles concerning medication palatability, nausea, and side effects remain significant barriers. Importantly, the tool appeared to foster increased treatment responsibility among some children, suggesting a potential pathway to improve therapeutic engagement and agency. This research underscores the XTEMP-R tool's potential to ease paediatric DR-TB treatment and highlights crucial areas for design refinement, ultimately aiming to enhance adherence and overall outcomes.
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Therapeutic Drug Monitoring: Affecting Factors

